Assessment of male pattern androgenic alopecia with topical niosomal minoxidil

2015 ◽  
Vol 72 (5) ◽  
pp. AB111
Keyword(s):  
Androgenic Alopecia ◽  
Male Pattern

Hair loss: a clinical update

2019 ◽  
Vol 8 (9) ◽  
pp. 422-429
Author(s):  
Lucy Millar-Hume ◽  
Farah Ali
Keyword(s):  
Hair Loss ◽  
Androgenic Alopecia ◽  
Levels Of Evidence ◽  
Female Pattern Hair Loss ◽  
Male Pattern

Hair loss is classified into non-scarring and scarring alopecias, the latter being further subdivided into primary and secondary forms. These classifications are also referred to as non-cicatricial and cicatricial hair loss. This article focuses on androgenic alopecia (AGA) and will, at times, be referred to as male pattern hair loss (MPHL) or female pattern hair loss (FPHL). Essentially, AGA is a non-scarring, benign form of alopecia, generally related to ageing and where, on the whole, a proportion of hair can grow back. Aestheticians should be prepared to answer a patient's questions and concerns and be familiar with the current levels of evidence surrounding the myriad of treatments available.

scholarly journals Clomiphene citrate rescue of spermatogenesis in men with infertility while remaining on finasteride: A case report

2017 ◽  
Vol 11 (3-4) ◽  
pp. 122 ◽  
Author(s):  
Christopher Wu ◽  
Ellen Forbes ◽  
Keith Allen Jarvi
Keyword(s):  
Case Report ◽  
Low Dose ◽  
Clomiphene Citrate ◽  
Oral Drug ◽  
Androgenic Alopecia ◽  
Normal Sperm ◽  
First Case ◽  
Sperm Counts ◽  
Male Pattern

Finasteride is a selective inhibitor of type-2 5-alpha reductase enzyme, preventing the conversion of testosterone to dihydrotestosterone (DHT). Finasteride is used as an oral drug for the treatment of benign prostatic hyperplasia at the 5 mg/day dose and is also used for the treatment of androgenic alopecia, or male pattern hair loss, at a dosage of 1 mg orally. There are now a number of studies documenting that finasteride, even at the low dose of 1 mg, may have an adverse effect on fertility for some men.In the largest study, Samplaski et al reported that sperm counts improved over 11-fold once the men had stopped the finasteride, but most of the men did not recover to normal sperm parameters. Presently, if men using finasteride are subfertile, the recommendation is to stop the finasteride and wait for a recovery of spermatogenesis. There has been no report of the use of any hormone therapy, such as clomiphene citrate, gonadotropin, or aromatase inhibitors, to treat subfertile men on finasteride. This is the first case report of the use of clomiphene citrate to improve fertilty for a man on finasteride.

scholarly journals Effects of Transcutol P and Precirol ATO-5 on Percutaneous Absorption of Flutamide from Emulgels

2021 ◽  
Author(s):  
Parandis Khalilollah ◽  
Javad Shokri ◽  
Seyedehzahra Ahmadi ◽  
Farnaz Monajjemzadeh
Keyword(s):  
Percutaneous Absorption ◽  
High Performance ◽  
Area Under The Curve ◽  
Diffusion Cell ◽  
Rat Skin ◽  
Androgenic Alopecia ◽  
Absorption Enhancers ◽  
Franz Diffusion Cell ◽  
Drug Concentrations ◽  
Male Pattern

Background: Flutamide is a non-steroidal anti-androgenic agent which is not only used in treating prostate cancer but also can be effective in some disorders such as androgenic alopecia and male pattern baldness. Several serious side effects for systemic administration of flutamide can be overcome by emulgel dosage form. Absorption enhancers can promote permeation of flutamide through skin. Percutaneous absorption of Flutamide emulgels with different concentrations of Transcutol P and Precirol ATO5 was studied. Methods: Various emulgel formulations using different concentration of Transcutol P and Precirol ATO5 with 0.5 to 5 % w/w were prepared. Percutaneous absorption was tested with standard Franz Diffusion Cell equipment using full thickness rat skin. Drug concentrations in the samples were analyzed by High-Performance Liquid Chromatography (HPLC) equipped with UV-Vis detector at 305 nm. Results: The percutaneous absorption of flutamide emulgels formulated with enhancers was higher than control formulations. Enhancement ratio increased from 1.218 to 3.670 and 1.346 to3.900 for Precirol ATO5 and Transcutol P, respectively. Area under the Curve (AUC) increased by increase the enhancers’ concentration and a significant upsurge was seen in the concentration 1% for both enhancers. Conclusion: The flutamide emulgel containing 1% Transcutol P showed more appropriate percutaneous absorption through the skin compared to others.

Frequency of Different Pattern of Hair Loss in Pakistani Men Using BASP Classification

2021 ◽  
Vol 15 (5) ◽  
pp. 1187-1189
Author(s):  
S. Nasreen ◽  
T. Malik ◽  
H. S. Memon ◽  
M. Izhar ◽  
S. M. S. Shah ◽  
...  
Keyword(s):  
Hair Loss ◽  
Cross Sectional Study ◽  
Androgenic Alopecia ◽  
Cross Sectional ◽  
Treatment Plans ◽  
Suitable Treatment ◽  
Surgical Treatments ◽  
Study Setting ◽  
Written Informed Consent ◽  
Male Pattern

Objective: To determine the frequency of different hair loss using BASP classification in Pakistani men. Study Design: Cross-Sectional Study. Setting: Study was conducted at Department of Dermatology, Abbasi Shaheed Hospital, Karachi. Duration: Six months starting 6th August 2019 till 5th January 2020 Material and Methods: Total 157 diagnosed patients with hair loss who met the diagnostic criteria were included. Brief history was taken and demographic information was recorded after taking written informed consent. Male pattern of hair loss (MPHL) was checked and categorized using BASP classification. Data was analyzed by SPSS 24.0. Results: In this study out of 157 patients, mean and standard deviation of age and duration of hair loss were 33.14±12.49 years and 1.89± 0.44 years, respectively. The Pattern of hair loss distribution showed that 34 (21.7%) were L type, 66 (42%) were M type, 35 (22.3%) were C type, and 22 (14%) were U type patterned hair loss. Conclusion: Assessment of male pattern hair loss using BASP classification found that M type hair loss was more prevalent. Currently, there are effective medical and surgical treatments available for men. However, the knowledge of pattern of hair loss in our population would help in choosing suitable treatment plans. Keywords: Male Pattern hair loss, Androgenic alopecia and BASP classification

Medical treatment of male pattern alopecia (androgenic alopecia)

1985 ◽  
Vol 7 (4) ◽  
pp. 336-339 ◽  
Author(s):  
Theodore A. Tromovitch ◽  
Richard G. Glogau ◽  
Samuel J. Stegman
Keyword(s):  
Medical Treatment ◽  
Androgenic Alopecia ◽  
Male Pattern

scholarly journals Is Every Patient of Hair Loss a Candidate for Hair Transplant?—Deciding Surgical Candidacy in Pattern Hair Loss

2021 ◽  
Author(s):  
Robert H. True
Keyword(s):  
Hair Loss ◽  
Body Dysmorphic Disorder ◽  
Young Patients ◽  
Androgenic Alopecia ◽  
Hair Transplantation ◽  
Detailed History ◽  
Hair Transplant ◽  
Female Pattern Hair Loss ◽  
Unrealistic Expectations ◽  
Male Pattern

AbstractPatterned hair loss which includes both male pattern hair loss (MPHL) or androgenic alopecia (AGA) and female pattern hair loss (FPHL) is the most common indication for hair transplant surgery. However, not all such patients are candidates for hair transplants. There are eight conditions that cause patients to not be appropriate candidates. These are: diffuse unpatterned alopecia (DUPA), cicatricial alopecia (CA), patients with unstable hair loss, patients with insufficient hair loss, very young patients, patients with unrealistic expectations, patients with psychologic disorders such as body dysmorphic disorder (BDD) and trichotillomania, and patients who are medically unfit. In addition, there are patients who are poor candidates and who should undergo hair transplantation only if they understand and accept limited results. The key to identifying these patients involves performing careful and detailed history and examination at the time of consultation.

Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia)

2015 ◽  
Vol 14 (3) ◽  
pp. 178-184 ◽  
Author(s):  
Katsuhiro Kure ◽  
Tsukasa Isago ◽  
Takeshi Hirayama
Keyword(s):  
Hair Loss ◽  
Sebaceous Gland ◽  
Androgenic Alopecia ◽  
Male Pattern

scholarly journals The potential of androgenic alopecia management from plant derivatives

Food Research ◽  
2020 ◽  
Vol 4 (S2) ◽  
pp. 1-13
Author(s):  
N.M. Noor ◽  
N.Z. Nazri ◽  
N.A. Mohamad-Salam ◽  
Z.I. Abdul-Rasid ◽  
R. Hasham ◽  
...  
Keyword(s):  
Hair Loss ◽  
Hair Growth ◽  
Self Esteem ◽  
Androgenetic Alopecia ◽  
Depression And Anxiety ◽  
Androgenic Alopecia ◽  
Growth Cycles ◽  
Male Pattern Baldness ◽  
Male Pattern

Hair loss or alopecia is a common dermatological issue that can affect millions of human population of all ages and both gender, male and female. Frequently, alopecia has been found to be associated with significant adverse effects or reduction of psychological and self-esteem. Consequently, this may lead to psychological problems such as depression and anxiety, thus it may negatively impact the quality of life as well. There are several types of hair loss including androgenetic alopecia (AGA), alopecia areata (AA), alopecia totalis (AT), Alopecia Universalis (AU), cicatricial alopecia (CA), senescent alopecia (SA), traction alopecia (TA) and telogen effluvium. However, this review will focus on the androgenic alopecia only. Androgenic alopecia (AGA) also known as male pattern baldness is referred to as hair loss that often occurs in men after puberty caused by the androgen. In addition, this review will discuss on the hair growth cycles and their mechanism on the androgenic alopecia and lastly the management of androgenic alopecia using plant derivatives and methods used in order to prolong the efficacy of androgenetic alopecia treatment.

Scalp Expansion for Male Pattern Baldness

1987 ◽  
Vol 14 (3) ◽  
pp. 469-475 ◽  
Author(s):  
Ernest K. Manders ◽  
Victor K. Au ◽  
Randolph K.M. Wong
Keyword(s):  
Male Pattern Baldness ◽  
Male Pattern
Sign in / Sign up

Export Citation Format

Share Document